ClinicalTrials.gg

Program

nucresiran

Also written as “Nucresiran” and “ALN-TTRSC04”.

Its studies are mostly in Cardiomyopathies · Polyneuropathies · Amyloidosis, led by Alnylam Pharmaceuticals.

Furthest: phase 3, since Jun 30, 20253 company-led studies, 2 open or runningNext primary completion: Dec 27, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alnylam Pharmaceuticals32 open or runningphase 3since Jun 30, 2025Dec 15, 2022Dec 27, 2027phase 3 · NCT07223203

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2022First study: phase 1 study in Transthyretin-Mediated AmyloidosisFirst studyNCT05661916 · 96 enrolled · United Kingdom
  2. Jun 30, 2025Phase 3 study in CardiomyopathiesNCT07052903 · 1,750 planned · United States, Argentina, Australia and more
  3. Oct 29, 2025Phase 3 study in PolyneuropathiesNCT07223203 · 125 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 27, 2027Primary completion: phase 3 study in PolyneuropathiesNCT07223203
  2. May 28, 2030Primary completion: phase 3 study in CardiomyopathiesNCT07052903

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07223203Polyneuropathies · United States, Argentina, Australia and more3RecruitingDec 27, 2027125
NCT07052903Cardiomyopathies · United States, Argentina, Australia and more3RecruitingMay 28, 20301,750
NCT05661916Transthyretin-Mediated Amyloidosis · United Kingdom1CompletedSep 30, 202596

How it is read

Names in the registry

  • “Nucresiran”, 2 entries
  • “ALN-TTRSC04”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.